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Abstract  
Studies   of   redox   proteomics   to   identify   glutathionylated   proteins   have   so   far   been  
focused  on  intracellular  proteins.  However,  plasma  proteins  have  been  described  as  
glutathionylated.  The  present  review  discusses  the  redox  state  of  protein  cysteines  in  
relation   to   their   cellular   distribution.   We   focus   in   particular   on   the   redox   state   of  
proteins   secreted   under   inflammatory   conditions   and   that   may   act   as   soluble  
mediators  (cytokines).  We  describe  the  various  approaches  used  to  detect  secreted  
glutathionylated   proteins,   the   only   thiol   modification   studied   so   far   in   secreted  
proteins,   and   the   specific   problems   presented   in   the   study   of   the   secretome.   This  
review  will  deal  with  a  particular  aspect  of  redox  proteomics,  the  analysis  of  secreted  
proteins  and  their  possible  function.  
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Redox  state  of  proteins  in  the  context  of  their  localization  
Redox  proteomics  of  the  thiol  proteome  
According   to   the  Oxford  English  Dictionary,  proteomics   is   “the  study  or  analysis  of  
the  set  of  proteins  expressed  by  an  organism”  and  we  commonly  apply  the  term  to  
high-­throughput   techniques   of   protein   identification.   As   such,   the   history   of   redox  
proteomics   started   in   2002  when   various   groups   published   the   first   reports   of   the  
identification   of   oxidized   proteins   by   modifying   the   existing   proteomic   techniques.  
Two   of   these   papers   were   aimed   at   carbonylated   proteins   (19,20)   and   others   at  
protein  glutathionylation  (33,37,61)  or  overall  protein  thiol  oxidation  (60)  .    
This   review  will  deal  with   the   redox  states  of  protein   thiols.  Biochemistry   textbooks  
and  protein  databases  classify  cysteines   in  proteins  as  either   free  or  engaged   in  a  
disulfide  bond.  However,  “free”  cysteines  can  be  reversibly  or  irreversibly  oxidized  to  
various  forms.  In  particular,  in  addition  to  forming  structural  disulfides,  cysteines  can  
form  transient,  reversible  disulfides  with  another  protein  cysteine,  with  free  cysteine  
(cysteinylation)   or   with   the   cysteine   in   the   tripeptide   glutathione   (GSH;;   glutamyl-­
cystenyl-­glycine).  Fig.    1  lists  the  most  important  oxidation  state  of  sulfur  in  cysteine.  
These  forms  of  oxidation,  due  to  their  reversibility,  are  of  great  interest  in  the  context  
of   redox   regulation,   as   a  means   by  which   the   redox   state   of   the   cell   can   regulate  
protein  functions  (43-­45).  
Specific  proteins  undergoing  glutathionylation  were  described  even  before   the  term  
“proteomics”  became  popular  (in   the   late  1990s,  according  to  Google  books  ngram  
viewer   -­   https://books.google.com/ngrams).   Two   proteins   have   been   identified   as  
undergoing  glutathionylation  in  two  separate  papers,  an  unidentified  30  kDa  cytosolic  
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protein   in   oxidant-­treated   rat   liver   (79),   and   actin   in   human   neutrophils   during  
oxidative  burst   (22).  Although   these  were  not   the   result  of  high-­throughput  studies,  
some   of   the   technologies   used   were   then   adapted   for   two-­dimensional   gels   for  
further   studies   and   are   at   the   basis   of   current   redox   proteomic   techniques.   In  
particular,  the  first  published  paper  using  the  expression  “redox  proteomics”  (37)  was  
substantially  based  on  the  application  of   the  technique  described  by  Rokutan  et  al.  
(79)  for  2-­dimensional  (2D)  gels.  
Most  redox  proteomic  studies  published  to  date  report   the   identification  of  cytosolic  
proteins  because   the  analyzed  samples  were  cell   lysates.  Studies  by   the  group  of  
Mike   Murphy,   specifically   focusing   on   mitochondria,   has   identified   several  
mitochondrial  proteins  susceptible  to  thiol  oxidation  (60).      Protein  abundance  is  also  
a  key  factor  in  the  identification  of  oxidized  proteins.  For  instance,  when  we  tried  to  
identify  specific  biochemical  pathways  targeted  by  protein  glutathionylation,  we  could  
identify   glycolytic   enzymes,   as   shown   in   Fig.   2,   suggesting   that   glycolysis   is  
potentially  regulated  by  the  redox  state  of  protein  thiols.    In  fact,  Fig.    2  also  shows  
that  many  of  the  glycolytic  enzymes  undergoing  glutathionylation  were  known  in  the  
literature   for   their  enzymatic  activity   to  be  affected   in  by   thiol  oxidation.  This  would  
predict   that   a   shift   in   the   GSH/oxidized  GSH   (GSSG)   ratio  may   affect   the   overall  
anaerobic   energy  metabolism.   However,   the   focus   on   glycolytic   enzymes  may   be  
due   to   the   fact   that   they   are   abundant   proteins,   which   preferentially   identified   by  
most  proteomics  techniques  (75).    
	   	   Ghezzi	  	  
	   5	  
  
Subcellular  localization  of  the  thiol  redox  state  
This   section   will   discuss   the   redox   state   of   protein   cysteines   in   different   cellular  
compartments.   It   will   provide   some   reason   for   the   high   prevalence   of   cytosolic  
proteins   among   those   undergoing   transient   post-­translational   modifications   (PTM),  
including  glutathionylation,  and  possibly  identify  understudied  areas  worth  exploring.    
  
Cytosol.  The   intracellular   environment   is   considered  a  highly   reducing  one,  mainly  
due  to  the  1-­10  mM  concentrations  of  GSH,  at  a  high  GSH/GSSG  ratio  (up  to  100/1).  
This   is   an   unfavourable   condition   for   the   formation   of   disulfide   bonds   and,   in   fact,  
structural  disulfide  bonds  are  normally  formed  in  the  endoplasmic  reticulum  that  is  a  
more  oxidizing  environment  (GSH/GSSG,  1/1)  (50).    
  
Plasma.  On   the   contrary,   the  extracellular   environment   is   oxidizing.  The  main   free  
thiol  in  serum/plasma  is  represented  by  cysteine,  but  that  is  only  in  the  range  of  10  
µM   and   with   a   reduced/oxidized   (cysteine/cystine)   ratio   of   1/6   (9).   GSH   is   also  
present  in  plasma  but  in  the  range  of  1  µM  (1,000-­fold  less  than  in  the  cell)  and  at  a  
GSH/GSSG  ratio  around  1  (9).  Other  studies  also  reported  that  plasma  GSH+GSSG  
is   present   at   at   least   10-­fold   lower   concentrations   than   Cys+cystine   but   while  
cysteine   is   mainly   oxidized   (Cys/cystine   ratio   around   1/10),   glutathione   is   more  
reduced,  even  extracellularly  (GSH/GSSG  ratio  of  10/2)  (57).  The  same  study  shows  
that   significant   amounts   of   cysteine   and  GSH   are   present   in   the   oxidized   form   in  
plasma  as  mixed  disulfides  with  proteins:  40%  of  total  plasma  cysteine  is  present  in  
cysteinylated   proteins   and   70%   of   plasma  GSH   is   oxidized   as  mixed   disulfides   to  
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form  glutathionylated  proteins  (57);;  by  comparison,  Brigelius  et  al.   (14,15)   reported  
that,  in  normal  liver,  1%  of  intracellular  GSH  is  present  as  glutathionylated  proteins.  
Hence,  even  if  total  plasma  glutathione  is  1/10  of  total  plasma  cysteine/cystine  and  is  
predominantly   in   a   reduced   state,   the   plasma   concentration   of   glutathionylated  
proteins   is   slightly  higher   than   that  of   cysteinylated  proteins,   raising   the   interesting  
question   of   whether   protein   glutathionylation   occurs   before   secretion.   Fig.      3  
summarizes  the  concentration  and  redox  state  of  thiols  in  the  cell  and  in  plasma  that,  
although  coming  from  the  studies  cited  above  and  obtained  in  different  models,  can  
provide  an  idea  of  the  order  of  magnitude  of  the  different  redox  states  of  cysteines.  
  
Structural  disulfides  in  cytoplasmic  versus  secretory  proteins  
Most  studies  on  protein  structure  point  out  that  cytosolic  proteins  have  no  disulfides  
while  extracellular  proteins  have  no  or   little   free  cysteines   (34,36,90).  Butera  et  al.  
(17)  have  calculated  that,  based  on  Uniprot  annotations  for  4,000  proteins,  about  half  
of   the   disulfide   bonds   are   in   membrane   proteins   and   the   other   half   in   proteins  
containing  a  secretion  signal  sequence,  but  about  5%  disulfide  bonds  are   found   in  
nucleoplasmic  or  cytoplasmic  proteins.    
Studies   using   diagonal   electrophoresis   in   primary   cardiac  myocytes   or   a   neuronal  
cell  line  have  shown  that  cytosolic  proteins  can  form  disulfide  bonds  upon  exposure  
to  oxidants  such  as  diamide  or  hydrogen  peroxide  (13,30).    These  studies  introduce  
the  class  of  transient  disulfides,  a  concept  that  Linke  and  Jakob  summarized  with  the  
title   “Not   every   disulfide   lasts   forever”   (62).   Disulfides   also   vary   in   their   surface  
exposure   and  while   the  most   surface-­exposed   are   easily   reduced,   those   buried   in  
the  three-­dimensional  structure  of  the  protein  require  prior  denaturation  of  the  protein  
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(16).   Accessibility   is   also   important   for   a   cysteine   to   be   susceptible   to  
glutathionylation,  because  of  the  size  of  GSH  (307  kDa).  This  is  even  more  important  
when  glutathionylation  occurs  by  thiol-­disulfide  exchange  with  GSSG  (612  kDa)  (45),  
and   even   more   if   this   reaction   is   catalyzed   by   glutaredoxin   (63).      It   is   likely   that  
transient  disulfides  are  also  surface-­exposed.  These  disulfides  can  be  intraprotein  or  
interprotein  ones  and  Brennan  et  al.  noted  that  many  of  them  imply  associations  with  
other  proteins  (13).  
  
Protein  thiols  on  the  plasma  membrane  
The   plasma  membrane   is   at   the   interface   of   the   intracellular   environment   and   the  
extracellular  one.  We  might  expect,  therefore,  that  protein  thiols  on  the  inner  side  are  
prevalently  reduced  and  the  ones  on  the  exofacial  side  prevalently  oxidized.    We  are  
not  aware  of  studies  attempting  a  quantification  of   the  redox  state  on  protein   thiols  
on  the  two  sides  of  the  membrane.    
However,  a  few  papers  reporting  the  existence  of  cell  surface,  exofacial,  thiols  have  
received   some   attention.   Early   studies   on   lymphocytes   showed   that   their   surface  
thiols  increased  upon  mitogenic  stimulation  (58).  Studies  overexpressing  or  inhibiting  
protein  disulfide   isomerase  (PDI)  showed  that   this  enzyme   is   important   for  keeping  
exofacial   thiols   in   the   reduced   state   (53).   Thus,   an   active   mechanism   could   be  
involved  in  the  presence  of  free  thiols  on  the  exofacial  side  of  the  plasma  membrane  
despite   the  extracellular  environment  being  oxidizing.     Redox  proteomics  has  been  
successfully  applied  to   identify  membrane  protein  whose  exofacial   thiols  are  redox-­
sensitive  (55,56).  
  
	   	   Ghezzi	  	  
	   8	  
The  secretome  
With   the   term   secretome  we   refer   to   proteins   that   are   released   in   the   cell   culture  
supernatant  or  found  in  circulation.  We  are  aware  that  a  conservative  use  of  the  term  
”secretion”  would   restrict   its  use   to  proteins   that  are  secreted   through   the  classical  
pathway  and  have  a  signal  sequence  for  targeting  to  secretion  via  the  Golgi  system.  
However,   the   term   “non-­classical   secretion”   is   often   used   to   define   non-­classical  
mechanisms;;   hence   our   use   of   the   term   “secretion”   instead   of   “release”   in   this  
review.  
  
Oxidized  proteins  in  circulation  
To  our  knowledge,  only  a   few  plasma  proteins  have  been  studied   in   terms  of   their  
redox  state.  
Serum   albumin   is   a   major   plasma   protein,   probably   the   most   abundant   secretory  
protein,   and   is   present   in   serum   at   concentrations   of   30-­50  mg/ml.   Human   serum  
albumin  has  17  cysteines  of  which  only  one  (Cys34)   is  not  engaged   in  a  structural  
disulfide.  Due  to  the  low  concentrations  of  free  thiols  in  plasma,  albumin  may  well  be  
the  main  thiol  antioxidant  in  circulation  (76,94).    This  can  undergo  oxidation  to  form  a  
mixed   disulfide   with   cysteine   (cysteinylation),   homocysteine   (32)   or   a   sulfinic   acid  
(66).   Increased   levels   of   cysteinylated   albumin   have   been   associated   with  
intrauterine  growth  restriction  (3).  
Transthyretin   is   a   transport   protein   (the   name  originates   from   “transports  thyroxine  
and  retinol”),  also   involved   in  amyloidosis   (83).   It   can  be   found   in  circulation   in   the  
0.5   mg/ml   range   as   S-­cysteinylated,   S-­cysteinglycinylated   and   glutathionylated  
(42,84).  
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High-­mobility  group  protein  box  1  (HMGB1)  is  a  nuclear  protein  that  can  be  released  
and   act   as   a   pro-­inflammatory   danger   signal   (97).   HMGB1   has   3   redox-­active  
cysteines  (Cys23,  Cys45,  Cys106).  The  different  redox  state  of  these  cysteines  also  
regulates   the   pro-­inflammatory   activity   of   HMGB1   (103).   In   circulation,   it   can   be  
found  with  an  intramolecular  disulfide  between  Cys23  and  Cys45  or  sulfonylated  on  
all  three  cysteines  and  its  oxidation  is  affected  in  acetaminophen  poisoning  (103).  
Pentraxin   3   (PTX3)   is   an   inflammatory   protein   related   to  C-­reactive   protein   that   is  
elevated   in  a  number  of   infectious,   inflammatory  and  cardiovascular  diseases   (12).  
Formation   of   disulfide-­linked   oligomers   of  PTX3  has   been   reported   and   one   study  
has  shown   that  measuring   its  oxidation  state  can  provide  a  superior  biomarker   for  
sepsis  than  measurement  of  total  PTX3  (29).  
  
Studies   specifically   addressing   the   proteomic   identification   of   the   redox  
secretome    
Despite  redox  proteomics  has  been  applied  to  the  thiol  proteome  looking  at  different  
forms  of  thiol  oxidation  (S-­nitrosylation,  transient  disulfides,  mixed  disulfides),  so  far  
high-­throughput  proteomics  of   the   thiol  secretome  has  only  been  applied   to  protein  
glutathionylation.  However,   these  are  very  recent  studies  and  hopefully  they  will  be  
followed  up  by  investigations  on  other  types  of  thiol  oxidation.  In  particular,  given  the  
high  concentration  of  extracellular  cysteine  it  will  be  important  to  identify  the  proteins  
released  as  cysteinylated.    
  
We   have   specifically   asked   if   proteins   can   be   released   as   glutathionylated   by  
inflammatory   macrophages.   To   answer   the   question,   we   have   used   a   strategy  
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employing   biotinoylated   GSH   ethyl   ester   (BioGEE),   originally   used   to   identify  
glutathionylated  proteins   in  HeLa  cells   (88).  The  principle   is  based  on   labelling   the  
intracellular  GSH  pool  with  biotinylated  GSH.  However,  because  GSH  is  poorly  cell  
permeable,   its  ethyl  ester   is  used   (98).  This   reagent   is  now  commercially  available  
and  has  been  used  in  over  150  papers  on  protein  glutathionylation.    
The   experimental   design   is   based   on   previous   publications   from   other   groups.  
Basically,  cells  are  preincubated  for  2  hrs  with  BioGEE,  washed  and  then  cultured  in  
reduced-­serum  medium  (Optimem;;  not  completely  serum  free  and  not  defined  as   it  
contains   a   proprietary   mixture   of   growth   factors)   with   or   without   an   inflammatory  
stimulus  (lipopolysaccharide,  LPS).  After  harvesting   the  supernatant,   free  thiols  are  
blocked  with  an  alkylating  agent   (such  as  N-­ethyl-­maleimide,  NEM)  to  prevent   thiol  
disulfide  exchanges.  Then  proteins  are  bound  on  streptavidin-­agarose  and  analysed  
by   mass   spectrometry.   The   proteins   on   the   beads   can   be   directly   digested   with  
trypsin   for   analysis  of   tryptic   peptides  or   eluted  with  dithiothreitol   (DTT).  The   latter  
approach  should  reduce  the  chances  of   identifying  proteins  non-­specifically  binding  
to   streptavidin   or   to   agarose   and   enrich   those   that   are   attached   to   streptavidin  
through  a  disulfide  bond  (Fig.4).    
Once  a   list   of   proteins   is   generated  by   the  mass   spectrometry   (MS)   analysis,   one  
has   to   bear   in   mind   that   this   proteomics   strategy   is   not   quantitative   but   is   highly  
sensitive  and  has  a  number  of  bias;;  for  instance,  the  proteins  identified  could  still  be  
bound  non-­specifically  to  the  beads,  or  be  a  result  of  the  non-­specific  leakage  from  a  
small   number   of   dead   cells.   Having   identified   a   protein   in   a   LPS-­stimulated  
supernatant  does  not  imply  that  its  secretion  is  induced  by  LPS,  also  because  there  
will  always  be  a  small  amount  of  secretion  by  resting  cells,  or,  again,  due  to  a  small  
amount  of  dead  cells.  Therefore,  it  is  imperative  that  each  protein  is  validated.    In  our  
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studies,  we  normally  provide  the  list  of  the  identified  proteins  as  supplementary  data  
but  report  only  those  validated  in  the  main  body  of  the  manuscript  (23).  This  makes  it  
possible  for  others  to  eventually  validate  other  proteins  of  interest.  
In  fact,  in  order  to  claim  that  a  protein  in  the  list  of  those  identified  by  MS  is  released  
as  glutathionylated  and  its  release  is  induced  by  LPS,  both  arms  of  the  claim  need  to  
be   confirmed.   Typically,   a  Western   blot   is   required   to   measure   the   protein   in   the  
supernatant  of  LPS-­stimulated  versus  unstimulated  cells.  This  should  be  done  with  a  
proper  number  of   replicates  and,  possibly,   followed  by  densitometry  and  statistical  
analysis  (23).  Of  course,   if  an  enzyme-­linked  immunosorbent  assay  (ELISA)  or  any  
other   assay   (such   as   an   enzymatic   assay   in   case   the   protein   is   an   enzyme)   are  
available,   that  would  be  preferable  as   it  may  be  more  quantitative   than  a  Western  
blot.  Demonstrating  that  a  protein  is  secreted  as  glutathionylated  is  more  difficult  as  it  
requires   immunoprecipitation  with  an  antibody  against   the  specific  protein   followed  
by   non-­reducing   gel   electrophoresis   and  Western   blot   with   an   anti-­GSH   antibody.  
Although  we  have  used  this  approach,  we  feel  it  is  not  always  satisfactory  due  to  the  
presence   of   non-­specific   bands   and   the   non-­optimal   migration   in   non-­reducing  
conditions   that   does   not   allow   an   exact   estimate   of   the   molecular   weight   of   the  
various   bands.   A   control   where   the   sample   is   run   under   reducing   conditions,   to  
remove  GSH   from   the  protein,  will   help.   Finally,   checking  on  a   database,   such  as  
Uniprot,   that   the   “glutathionylated”   proteins   identified   actually   have   a   free   cysteine  
available  for  glutathionylation  will  avoid  embarrassing  mistakes.  
In   some   cases,   of   course,   the   glutathionylated   protein   may   have   already   been  
detected   by   the  MS   analysis   of   the   proteins   or   their   peptides   at   the   stage   of   the  
identification.   Identification   of   a   glutathionylated   peptide   will   also   provide   the  
additional  information  of  which  cysteine  is  glutathionylated.  However,  many  protocols  
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for   MS   analysis   include   a   reducing   step,   making   thus   impossible   to   identify  
glutathionylated  peptides.  
  
Proteins  in  the  redox  secretome  
Glutathionylated  proteins  
Table  1   lists  proteins  secreted  as  glutathionylated  by  LPS-­stimulated  macrophages  
identified  as  described  above.  Below  we  discuss  some  of  them.  
Redoxins    Three  proteins  in  the  list  are  involved  in  redox  regulation  and  were  the  first  
ones   we   validated.   In   fact,   we   had   previously   identified   by   redox   proteomics  
intracellular   peroxiredoxin   (PRDX)   1   (37)   and   thioredoxin   (TRX)   1   (18)   among   the  
proteins  undergoing  glutathionylation  in  human  lymphocytes.    
Thioredoxin   is   a   protein   thiol/disulfide   oxidoreductase   catalysing   a   thiol-­disulfide  
exchange   reaction.   Although   its   most   important   function   is   to   keep   ribonucleotide  
reductase  in  the  reduced  state,  and  thus  is  essential  for  DNA  synthesis  (49),  it  has  a  
broad  substrate  specificity  and  can  reduce  hundreds  of  proteins  (73)  with  the  overall  
reaction  (1)  below:  
(1)  TRX-­(SH)2  +  Protein-­oxidized  à  TRX-­S-­S  +  Protein-­reduced  
The   oxidized   TRX   is   then   reduced   back   by   the   NADPH-­dependent   selenoprotein  
enzyme  TRX  reductase.  
Under  oxidative  conditions,  such  as  in  the  absence  of  TRX  reductase  to  regenerate  
TRX   in   its   reduced   state,   TRX   can   act   as   an   oxidant   (39)  with   the   reverse   of   the  
reaction   above.      TRX   has   long   been   known   to   be   secreted   and   was   originally  
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described   by   the   group   of   Yodoi   as   a   leukaemia   cell   product   that   stimulates  
lymphocyte  proliferation  (89,96).  
Peroxiredoxins  are  TRX  peroxidases  and  use  reduced  TRX  as  the  electron  donor  in  
eliminating  H2O2.  During  its  catalytic  action,  PRDX  is  first  oxidized  by  H2O2  and  then  
reduced  by  TRX-­(SH)2  with  the  resulting  reaction  (2)  below:  
(2)  TRX-­(SH)2  +  H2O2  à  TRX-­S-­S  +  H2O2  
PRDXs   have   a   very   high   specificity   for   TRX   and,   in   general,   cannot   use   other  
proteins  as  substrates.  
It   is   very   interesting   that   both   PRDXs   and   their   substrate   are   co-­released   under  
inflammatory   conditions.   We   have   hypothesized   elsewhere   that,   because   the  
extracellular  environment  is  an  oxidizing  one,  lacking  glutathione  and  NADPH,  these  
two  proteins  could  act  in  concert  to  oxidize  other  proteins  (81).    
Secretion  of  PRDXs  has  also  been   reported  previously,  when   these  proteins  were  
originally  termed  natural  killer  cell  enhancing  factors  (40).  
Profilin   and   vimentin   were   also   identified   among   the   intracellular   glutathionylated  
proteins   in   our   pioneering   redox   proteomics   study   (37).   Profilin   has   already   been  
reported   by   a   previous   study   in   the   human   immunodeficiency   virus   1   (HIV-­1)   -­
infected,   monocyte-­derived   macrophage   secretome,   although   that   study   did   not  
investigate  its  redox  state  (54).  Like  profilin,  vimentin  was  also  identified  previously  in  
the  macrophage  secretome,  although  its  redox  state  was  not  investigated  (54,68).  
  
Other  forms  of  thiol  oxidation    
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In   addition   to   glutathionylation,   disulfide-­linked   homodimerization   has   also   ben  
reported   in   secreted   proteins.      We   found   that   PRDX1   and   PRDX2   need   to   form  
disulfide-­linked   homodimers   in   order   to   be   secreted.   Mutation   of   the   cysteine  
involved   in   homodimerization,   but   not   of   other   cysteines,   prevents   their   secretion  
(70).  
A   similar   observation   was   made   for   fibroblast   growth   factor   1   (FGF1)   where  
dimerization  occurs  during  its  secretion  (67)  and  mutation  of  those  cysteine  involved  
in  homodimerization  blocks  it  (51).  
In  the  case  of  PRDX1  and  2,  disulfide-­linked  dimerization  targets  them  for  secretion  
via   the  exosomal   route,  while  FGF1   is   then  secreted  as  part  of  a   larger  multimeric  
complex  (67).    
  
Secretion  of  carbonylated  proteins  
In   terms   of   irreversible   oxidative   damage,   redox   proteomics   studies   on   oxidatively  
damaged  proteins  by  the  Butterfield’s  group  have  found,  increased  carbonylation  in  
some   circulating   protein   in   Alzheimer   Disease,   including   haptoglobin   β   chain,  
serotransferrin  and  α2-­Macroglobulin  (28).  
  
The  problem  of  cell  lysis  contamination  in  secretome  studies  
Whenever   studying   non-­classical   secretion   of   proteins,   the   problem   arises   as   to  
whether  their  presence  in  the  cell  culture  supernatant  is  due  to  secretion  or  if  it  is  an  
artefact   due   to   leakage   from   a   small   amount   of   dying   cells   in   the   culture.   This  
problem   is   often   addressed   with   a   shortcut,   where   cell   toxicity   is   measured   by  
Trypan  blue  exclusion  or  by  assays  where  cell  viability  is  assessed  by  a  colorimetric  
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or   fluorometric   metabolic   assay   such   as   those   employing   the   oxidation   of   3-­(4,5-­
dimethylthiazol-­2-­yl)-­2,5-­diphenyltetrazolium   (MTT).   The   risk   that   release   of   the  
protein  may  be   due   to   non-­specific   leakage   from  dead   cells   is   then   ruled   out  with  
statements   like   “cell   viability   was   over   95%”   or   “cell   death   was   less   than   5%”.  
However,   the   real  question   is  whether   that  5%   (or  even  a  0.5%)  of   cell   death  can  
account  for  the  observation  that  a  protein  is  present  in  the  secretome.    
We   have   addressed   this   problem   by   assessing   not   only   the   cell   viability,   as  
described   above,   but   also   the   percentage   of   cell   death   that   would   be   required   to  
account   for   the  amount  of   protein   released   in   the  supernatant.  For   instance,   if   the  
cells  are  cultured  in  24-­well  plates  in  1  ml  of  culture  medium  that  is  then  analysed  to  
measure  the  secreted  proteins,  parallel  samples  should  be  set  up  in  the  same  way  
and  the  cells  then  lysed  in  1  ml  of  buffer.  Then  comparable  volumes/dilutions  of  the  
cell   lysate   or   the   supernatant   should   be   analyzed   by   Western   blot.   Using   this  
approach  to  the  study  of  PRDX1  secretion,  for   instance,  we  calculated  that  at   least  
40%   cell   death  would   be   required   to   account   for   the   observed   release   of   PRDX1  
(23).    
An   alternative   approach   is   to   measure   the   release   of   an   irrelevant   intracellular  
protein,   such   as   actin.      Although   we   have   done   so   (23),   this  may   not   work   in   all  
experimental  models  as  in  some  cases  actin  may  be  also  secreted  (54).  In  general,  
we  strongly  recommend  a  combination  of  all  these  methods  to  rule  out  non-­specific  
leakage.  
  
Methods   of   proteomics   analysis   with   specific   consideration   to   problems  
arising  from  the  study  of  secreted  proteins  
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A  wide   range   of  methodologies   are   used   to   characterize   cellular   secretomes   (69).  
Among   them,   the   recent   advances   in   liquid   chromatography   tandem-­mass  
spectrometry   (LC-­MS/MS)-­based   shotgun   proteomic   techniques   have   provided  
powerful   tools   for   targeted   or   non-­targeted   protein   identification   and   quantification  
strategies.   Conditioned   media,   with   or   without   serum   supplementation,   has   often  
been  used  in  secretomics  and  unfortunately  in  such  complex  biological  samples,  the  
proteins   of   interest   are   generally   present   in   small   amounts,   are   highly   diluted   and  
may   be   masked   by   more   abundant   serum   proteins.   To   overcome   the   problem   of  
large  dynamic  range  between  low  and  high  concentration  proteins,  the  strategies  of  
sample   preparation   and   MS-­based   analysis   should   be   adapted   (see   Fig.   5   for   a  
global   view   of   the   possible   strategies).      Pre-­fractionation   of   proteins   (top   down  
approach)   or   peptides   (bottom   up   proteomics)   with   high   resolution   separation  
methods   can   be   applied   to   decrease   the   complexity   of   samples.   Use   of   the   new  
generation  of  high-­resolution  mass  spectrometry  (MS)  can  allow  quantitative  in-­depth  
large   scale   protein   expression   and   characterization   in   complex   mixtures.   All   the  
different  aspects   (cell  culture,  sample  preparation,   fractionation  methodologies,  MS  
technologies,   quantitative   profiling   of   dynamic   secretomes,   and   data   analysis)   are  
discussed  below.  
  
Culture  media  and  sample  preparation  
Here  we  discuss  some  general  considerations  of  cell  culture,  sample  concentration  
and  cleanup  that  should  be  done  with  the  minimum  number  of  steps  to  limit  the  loss  
of   protein   before   pre-­fractionation.   To   avoid   contamination   of   low-­abundance  
proteins  secreted  by  cells,  a  serum-­free  culture  medium  should  be  used,  whenever  
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possible;;   phenol   red-­free  media   is   also  preferred  as  phenol   red  may   interfere  with  
MS  analysis  and  is  very  difficult  to  eliminate.  Conditioned  medium  should  be  spin  at  
high  speed  (20,000  g  at  4°C)  in  order  to  eliminate  cell  debris.  Concentration  of  large  
volumes  of  medium  can  be  done  by  freeze-­drying  (10)  or  ultrafiltration,  for   instance  
on  Amicon  Ultra-­15with  3  KDa  cut-­off  membrane(Millipore);;  this  filtration  device  also  
enables  desalting,  as  culture  media  have  many  chemical  compounds  like  salts  and  
amino   acids   which   interfer   with   MS   though   ion   suppression;;   ultrafiltration   also  
enables  buffer  exchange  before  fractionation  or  protease  in-­filter  digestion,  described  
as  Filter  Aided  Sample  Preparation  (FASP)  (100).  Protein  precipitation  using  organic  
solvents   (such   acetone)   or   trichloroacetic   acid   is   another   option   to   achieve   both  
protein   concentration   and   elimination   of   undesirable   molecules   (46)   although  
subsequent  re-­solubilization  of  the  precipitated  proteins  may  be  difficult.  
Prior   to   proteomic   analysis,   some   authors   used   multiple   immunoaffinity   depletion  
methods  (e.g.  SIGMA  ProteoPrep20)  to  remove  some  of  the  most  abundant  plasma  
proteins  (91),  or  protein  equalizer  technology  like  combinatorial  peptide  ligand  library  
(BioRad  ProteoMiner)      (77  ,92);;  sometimes   the   two   technologies  are  used   to  allow  
enrichment   of   proteins   in   biological   fluids   for   in-­depth   proteomic   analysis   (11).  
Independent  of   the  strategy  used,  proteins  need  to  be  reduced,  alkylated,  digested  
by  proteases  (trypsin,  chymotrypsin,  LysC),  labeled  and  desalted  on  C18  before  MS  
analysis.    
Quantitative  proteomic  profiling  by  mass  spectrometry  
Due  to  the  complexity  and  broad  dynamic  range  of  proteins  in  cell  secretomes,  pre-­
fractionation   techniques   are   necessary   to   reduce   the   complexity   of   conditioned  
medium   and   to   enhance   proteome   coverage   enabling   the   identification   of   more  
proteins  by  MS.  The  two  main  proteomic  approaches,  top  down  and  bottom  up,  are  
	   	   Ghezzi	  	  
	   18	  
presented  in  this  section.  Particular  attention  will  be  given  to  shotgun  proteomics  with  
peptide   labeling  or   label-­free,  emerging  strategies   that   take  advantage  of   the  most  
recent   advances   in   separation   technology,   high   scan   speed   and   high-­resolution  
analyzers.  We   will   also  mention   targeted   proteomic   by  Multiple/Selected   Reaction  
Monitoring  (MRM/SRM).    
Top  down  proteomics  
In  the  offline  strategy,  proteins  are  first  separated  either  by  gel-­based  methods,  liquid  
chromatography  or  mixed  methods,  digested  by  proteases  and  then  analyzed  by  MS  
(nanoLCMS/MS,  MALDI-­TOF,  MALDI-­TOF/TOF).  
The  classical  proteomic  approach  involves  2-­dimensional  gel  electrophoresis  (2-­DE)  
and   d	   ifference   gel   electrophoresis   (DIGE)   which   enables   protein   separation   by  
isoelectric   focusing   (IEF)  according   to   their   isoelectric  points   in   first  dimension  and  
SDS-­PAGE  according   to   their  molecular  weight   in   the   second  dimension   (38,106).  
Protein  spots  are   then  visualized  by  staining  with  Coomassie  blue,  silver  nitrate  or  
fluorescent  dyes   (such  as  SYPRO  Ruby).  After  gel   imaging,  gels  are  quantitatively  
analyzed   using   an   image   analysis   software   and   the   spots   of   interest   are   excised  
from  gel  and  treated  as  described  above  before  identification  by  MS.  
A  combination  of  multidimensional  separation  methods,  including  C4  reverse  phase  
liquid   chromatography   (RPLC)   (35),   off   gel   electrophoresis   (65)   and   SDS-­PAGE  
(74),    can  be  used  to  separate  proteins  in  the  first  dimension.  Collected  fractions  or  
gel   slices   are   then   subjected   to   trypsin   digestion.   Peptides   are   subsequently  
desalted   and   analyzed   online   by   nanoLC-­MS/MS   with   an   electrospray   ionization  
interface  (ESI).  
Capillary  electrophoresis  (CE)  can  be  directly  interfaced  with  mass  spectrometers  via  
ESI   and   used   for   intact   protein   characterization   taking   advantage   of   an   excellent  
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resolution   size-­sorted   capacity   and   a   good   sensitivity   (105).Top   down   approaches  
using  CE   allow   elucidation   of   complex   post-­translational  modifications   to   generate  
information   on   protein   isoforms   (59).   However,   top   down   proteomics   allow   limited  
proteome  coverage  identification  compared  with  a  bottom  up  approach.  
  
Bottom-­up  shotgun  proteomics  
Bottom  up  shotgun   is  a  modern  strategy,  now  widely  used   in   large  scale,  detailed,  
relative  quantitative  protein  profiling  in  complex  mixtures.  Recent  advances  in  MS  led  
to   the  development   of   several  methods   for   relative  protein   quantification,   including  
isotopic   labeling:   stable   isotope   labeling   by   amino   acids   in   cell   culture   (SILAC),  
isobaric  tags  for  absolute  and  relative  quantification  (iTRAQ),  isobaric  tandem  mass  
tags   (TMT),   isotope-­coded   affinity   tags   (ICAT)   and   16O/15O.   Alternative   methods  
include  MRM/SMR,  or  label-­free  methods  based  on  peptide  intensity  measurements.  
SILAC   is   based  on   in   vivo   incorporation  of   isotope   labeled  amino  acids   (Lys,  Arg)  
into  de  novo  synthesized  proteins  during  cell  culture  (72).  After  treatment,  cell  culture  
media  from  the  two  samples  are  combined  and  subjected  to  sample  preparation  as  
described   above.   Several   orthogonal   separation   techniques   can   be   used:   purified  
proteins   are   separated   by  SDS-­PAGE   (74)   and   in-­gel   trypsin-­digested   or   desalted  
peptides   are   first   fractionated   by   strong   cation   exchange   (SCX)   (87).   Then,   all  
subsequent   fractions,   either   from   SDS-­PAGE   or   SCX,   are   subjected   to   reverse  
phase  nanoLC-­MS/MS  analysis.  
Other   in   vitro   label-­based   techniques   have   also   been   used:   e.g.   addition   of  
light/heavy   chemicals   to   each   protein   cysteinyl   residue   with   ICAT   reagents   (47),  
differential  labeling  at  N-­terminal  group  of  digested  peptides  with  iTRAQ  (80),  or  TMT  
reagents  (87)  and  labeling  of  digested  peptides  at  the  C-­terminal  with  16O/15O  (11).  
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Note  that  in  these  approaches,  all  labeled  peptides  are  chemically  identical  and  co-­
elute  during  the  chromatographic  separation  step  but  have  different  masses  that  can  
be  resolved  by  MS.  
In   the   ICAT   method,   proteins   from   two   biological   samples   (e.g.   control   cells   and  
treated   cells)   are   labeled   independently,  mixed   before   trypsin   digestion   and   ICAT-­
labeled  peptides  are   isolated  by  affinity  biotin   tag;;  enriched  peptides  are  separated  
online  by  nanoLC-­MS/MS  or  offline  by  MALDI-­TOF/TOF.  The  relative  quantification  
of   protein   amount   is   determined   by   the   ratio   of   the   peptide   pairs   and   MS/MS  
fragmentation-­based  peptide/protein  identification.    
The  iTRAQ  and  TMT  methods  are  particularly  attractive  quantification  techniques  in  
shotgun   proteomics,   mainly   due   to   the   possibility   of   labeling   up   to   eight   (iTRAQ-­
8Plex,   SCIEX)   or   ten   (10plex   TMT,   Thermo  Scientific)   different   biological   samples  
which   can   then   be   simultaneously   analyzed   in   a   single   experiment.   In   brief,   the  
sample   workflow   is   the   following:   purified   proteins   extracts   are   reduced,   alkylated  
and  digested,  and  the  peptides  contained    in  each  sample  are  labeled  by  reagents,  
mixed  together  before  pre-­fractionation  by  different  techniques  (SXC)  (93).  Then,  all  
the   fractions   obtained   are   analyzed   by   high-­resolution   nanoLC-­MS/MS   which  
identifies   peptides   and   the   relative   abundance   of   protein   in   the   different   samples,  
using  the  ratio  of  reporter  ions  released  during  the  fragmentation  step.  For  either  top  
down   or   bottom   up   proteomics,   dedicated   database   search   algorithms   (Matrix  
Science   MASCOT,   Agilent   Technologies   SPECTRUM   MILL,   Thermo   Finnigan  
SEQUEST,   Bioinformatics   Solutions   Inc.   PEAKS   DB)   are   used   for   protein  
identification.   Also   for   both   in   vitro   and   in   vivo   labeling   approaches,   dedicated  
bioinformatic  tools  are  used  for  the  relative  protein  quantification:  iQuantitator  (85)  for  
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iTRAQ,  MaxQuant  (97)  and  MassChroQ  (98)  for  SILAC  are  cited  as  examples  (see  
Fig.  5  for  more  details).  
Besides   labeling-­based   techniques,   label-­free   quantification   has   become   the   new  
generation  in  shotgun  proteomic  strategies,  taking  advantage  of  recent  advances  in  
separation   technology   and   in   MS.   At   present,   identification   of   5,000   proteins   is  
attainable   in   a   standard   90-­min   gradient   with   nanoLC   ultra-­high-­pressure   HPLC  
system  coupled  online   to  modern  high   resolution  mass  spectrometers   (5,82).     Two  
MS   label-­free   data   analysis   pipelines   can   be   applied.   The   first   uses   the   spectral  
count,  which  is  based  on  the  frequency  number  of  identified  total  MS/MS  spectra  of  
the   same   protein   in   each   of   the   datasets   (27).   The   second   approach   is   based   on    
measurement   of   changes   in   chromatographic   peptide   ion   intensity,      detecting  
peptides  by  MS,  matching   the   corresponding  peptides  across  multiple  LC/MS  runs  
using   their  mass-­to-­charge  and   retention   time,  selecting  discriminatory  peptides  by  
matching   peak   area   integration   on   extracted   ion   chromatograms   with   specific  
software:  Progenesis  QI   (Nonlinear  Dynamics),  Mass  Profiler  Professional   (Agilent  
Technologies),  MaxQuant   (Max   Planck   Institute   of   Biochemistry)   and  MassChroQ.  
The   final  step   is   identification  of   regulated  peptides  by   targeted  MS/MS.  Label-­free  
MS  strategies  have  many  advantages,  including  low  cost,  high-­throughput  (no  limit  to  
the   number   of   samples   and   conditions   that   can   be   compared),   time,   as   sample  
preparation   is   easy   (based  on  SDS-­PAGE  stacking   gel   purification/in-­gel   digestion  
(99)  or  in-­filter  digestion  using  FASP  (101)).  
Targeted  proteomics  
As   part   of   a   discovery   strategy,   SRM,   also   called   MRM,   is   a   method  
of  absolute  quantification   in   targeted  proteomic   analyses   and   is   usually   carried   out  
on   triple-­quadrupole  mass   spectrometers   (QQQ).   In   this  method,   isotopic   absolute  
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quantification  (AQUA),  peptides  are  spiked  in  complex  samples  and  used  as  internal  
standards  (41,95).  AQUA  peptide  is  designed  to  be  identical  to  the  prototypic  target  
peptide  generated  by  sample  digestion.  Both  peptides  co-­elute  in  a  known  retention  
time   window   and   are   analyzed   simultaneously.   The   concentration   of   the   target  
peptide  is  then  determined  by  measuring  the  signal  response  for  the  target  peptide  
relative  to  that  of  the  AQUA  peptide.  In  the  MRM  mode,  a  particular  pair  of  parent  ion  
and  several  fragments  are  selected  and  detected  to  ensure  the  specific  detection  of  
low-­abundance   proteins   in   highly   complex  mixtures.   The   SRM  method   is   specific,  
highly  sensitive  and  is  a  useful  tool  for  high-­throughput  screening  of  biomarkers  in  a  
very  large  number  of  clinical  samples.  
  
Redox  arrays  
We   soon   realized,   in   the   course   of   our   studies   on   redox   proteomics   of  
glutathionylated  proteins,  that  some  proteins  are  found  over  and  over  in  proteomics  
studies.  In  fact,  this  is  a  very  well-­known  bias  of  the  proteomics  approach.  While  MS  
is   very   sensitive,   in   a   mixture   of   proteins   the   abundant   ones   are   identified   more  
easily  and  can  mask  the  less  abundant  ones  (75,78).  For  instance,  PRDXs  account  
for  up  to  1%  of  total  cellular  proteins  (102).  It  is  very  likely  that  we  would  miss  most  
of  the  cytokines  or  components  that  are  present  in  the  secretome  at  concentrations  
in  the  range  of  picogram/ml.    
We   have   tried   to   circumvent   this   problem   setting   up   a   technology   that   we   called  
“redox   arrays”   and   that   are   based   on   commercially-­available   antibody   arrays   (71).  
These  are  membranes  or  glass  slides  coated  with  antibodies  to  up  to  1,000  different  
proteins   and   are   used   to   identify,   in   a   semiquantitative   manner,   proteins   that   are  
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differently  expressed  in  different  samples.  We  have  adapted  this  approach  to  identify  
proteins  undergoing  glutathionylation  in  the  inflammatory  secretome.  This  strategy  is  
outlined  in  Fig.  6.  The  first  part  is  based  on  the  use  of  BioGEE  to  attach  a  biotin  tag  
to   glutathionylated   proteins   described   above   (section   2.3).   Then   the   supernatant,  
containing  biotinylated  (glutathionylated)  and  non-­biotinylated  (non  glutathionylated)  
proteins,  is  applied  to  a  membrane  array  (we  used  an  antibody  arrays  consisting  of  
1,000  antibodies  immobilized  on  nitrocellulose  membrane  by  Raybiotech,  Norcross,  
USA),   the  membranes  are  washed  as  per   the  manufacturer’s   instruction  but   taking  
care   of   avoiding   the   use   of   any   reducing   agent   (included   in   most   protocols)   that  
would   remove   the   biotin   tag.     Detection   with   streptavidin-­peroxidase   followed   by  
enhanced  chemiluminescence  (ECL)  will   reveal  a  dark  spot   if  a  protein   is   released  
as  glutathionylated.  DTT-­treated  samples  will  allow  identifying  false  positive  spots.  If  
a  protein  is  released  but  not  glutathionylated,  it  will  not  show  up.    
Using  this  approach,  both  for  the  secretome  and  for  the  cell  lysate,  we  could  identify  
80   potential   glutathionylated   proteins,   most   previously   unrecognized   to   be  
glutathionylated.  We  use   the  word   “potential”  because   the  same  caution  should  be  
used  as   in   the  MS  identification  and  require  validation  as  described  above  (section  
2.2).   In   our   methodological   study   we   validated   two   such   proteins,   soluble   IL-­1  
receptor  type  II  (IL-­1sRII)  in  the  secretome  and  the  tyrosine-­protein  kinase  Lyn  is  the  
intracellular  fraction  (71).  
We   have   tried   to   establish   if   this   method   would   allow   the   identification   of   low  
abundance   proteins   and   compared   the   proteins   identified  with   this   study   (71)  with  
our  previous  study  using  redox  proteomics  based  on  2D  gels  (37),  that  of  the  study  
mentioned   in   section  2.3.1  based  on   the   labelling  with  BioGEE   followed  by  affinity  
purification  on  streptavidin  and  shotgun  proteomics   (23),  as  well  as  with  a  curated  
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database,   dbGSH,   of   known   glutathionylated   proteins   identified   so   far  
(http://csb.cse.yzu.edu.tw/dbGSH/)  (24).  We  then  used  a  published  list  of  over  7,000  
human  proteins  ranked  by  their  abundance  in  a  human  osteosarcoma  cell  line    (4)  to  
calculate   the   expected   frequency   distribution   of   human   proteins   according   to   their  
abundance.    Although  these  data  are  only  indicative,  as  they  are  obtained  in  different  
cells,   ranging   from   human  T   lymphocytes   (37)   to  mouse  macrophage   (23,81)   and  
human  monocytic  leukemia  cells  (71),  still  the  study  on  the  osteosarcoma  cell  line  we  
refer  to  has  PRDX1,  vimentin  and  profilin  in  the  20  most  abundant  proteins  (4).  The  
frequency  distribution  in  the  reference  study  is  shown  in  Fig.7A.  We  refer  to  this  as  
the   “expected”   frequency   distribution   of   proteins   with   different   abundance   and  
compare   with   that   found   in   the   various   redox   proteomics   experiment   of  
glutathionylated  proteins  performed  by  us   from  2002  to  date,  as  well  as   that  of   the  
proteins  present  in  the  curated  database.  This  was  done  on  the  assumption  that  the  
protein   abundance   is   similar   across   the   different   cells,   which   is   of   course   an  
approximation.    
Fig.7B   compares   the   distribution   of   glutathionylated   proteins   found   with   our   first  
method   based   on   radiolabeling   of   GSH   with   35S,   2D   electrophoresis   followed   by  
autoradiography,   spot   picking   following   Coomassie   blue   staining   and   MS  
identification   (37).   It   can   be   seen   that   the   proteins   identified   are   heavily   skewed  
toward  the  high-­abundance  ones,  as  one  may  expect  from  a  study  using  Coomassie  
blue  staining.  The  identification  appears  less  skewed  in  our  more  recent  approaches  
based  on   the  use  of  BioGEE  and  MS   identification   (23,81)   (Fig.7C).   It   is   improved  
further   in  the  curated  database  that  clearly   includes  mainly  proteins  from  proteomic  
studies  but  also  proteins   from  studies  aimed  at  specific  proteins,  and  not   involving  
their   identification  by  proteomics   (Fig.7D).  The   frequency  distribution  obtained  with  
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the   redox   array   method   (taken   from   (71)   is   surprisingly   close   to   the   expected  
distribution   for  an  unbiased  method   (Fig.7E).  Needless   to  say,   this  approach   is   far  
from   being   unbiased   as   the   proteins   for   which   the   antibodies   are   spotted   on   the  
arrays   are   selected   based   on   some   criteria.   For   instance,   if   we   were   to   use   an  
antibody  array  for  cytokines  and  growth  factors,  the  frequency  distribution  would  be  
skewed   in   favour   of   low-­abundance   proteins   because   most   cytokines   are   not  
expressed  constitutively  and,  even  when  induced,  are  in  the  picogram  range.    
We   think   that   the   strategy   based   on   redox   arrays   can   be   tailored   to   identify   other  
forms  of  oxidation  or  transient  disulfides.    For  instance,  it  could  be  coupled  to  biotin  
switch   approaches   using   reductants   specific   for   S-­nitrosylated   proteins   (52).      We  
believe  this  technique  might  represent,  for  the  field  of  redox  biology,  an  equivalent  to  
the  arrays  used  to  study  the  kinome  and  the  phosphoproteome.    
  
Biological  significance  
Biomarkers  of  the  redox  state  
The  most   obvious   relevance   of   the   redox   secretome   is   in   biomarker   discovery.   In  
fact,  secreted  proteins  are  likely  to  be  detectable  in  circulation  –  an  almost  essential  
feature  for  a  successful  biomarker.  Because  reactive  oxygen  species  are  short-­lived,  
it   is   impossible   to  measure  any  of   them   in  biological   fluids  and  we  have   to   rely  on  
biomarkers  as  proxy  indicators.    Oxidized  proteins  (such  as  carbonylated  proteins  or  
glutathionylated   proteins)   can   be   an   indicator   of   the   redox   state   of   the   organism  
provided   they   are   prepared   properly.   In   particular,   for   thiol-­oxidized   proteins   it   is  
essential  to  treat  the  sample  with  NEM  or  another  alkylating  agent  before  storage,  in  
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order   to   prevent   thiol-­disulfide   exchange   reaction   with   protein   thiols   or   small-­
molecular  weight  thiols.  
Although   not   a   secreted   protein,   many   studies   have   measured   glutathionylated  
haemoglobin   in   many   disease   conditions   and   found   an   association   with   some   of  
them   (reviewed   in   (45)).   The   same  approach   could   be  used   for   secreted  proteins.  
Oxidized  proteins   could   be  of   the   same  use  as  glycated  haemoglobin   in   diabetes,  
that  does  not  just  reflect  to  the  level  of  glucose  at  a  given  time  point  but  really  is  an  
indicator  of  the  exposure  of  the  organism  to  high  glucose  (21).  As  mentioned  earlier,  
the  example  of  PTX3  suggests  that  the  redox  state  of  a  biomarker  may  represent  an  
additional  dimension,  improving  its  diagnostic  or  prognostic  significance  (29).  
  
Functional  significance  
We   think   the   study   of   the   redox   secretome   can   lead   to   the   identification   of   novel  
soluble  mediators  (cytokines).  Probably  the  best  example  of  this  is  thioredoxin  which  
was  discovered  by  Arne  Holmgren  in  Stockholm  as  a  reducing  cofactor  essential  for  
the  catalytic  action  of   ribonucleotide   reductase  and  by   Junyi  Yodoi   in  Kyoto  as  an  
adult   T-­cell   leukaemia   derived   factor;;   Yodoi   was   expecting   to   have   identified   an  
interleukin-­1  gamma  but  once   the  protein  was  sequenced   it  was   identified  as  TRX  
(104).   Also   PRDXs   were   first   identified   as   natural   killer   (NK)   cell   activators   even  
before  their  enzyme  activity  was  established  (85).  The  main  cytokine-­like  activities  of  
redoxins  are  summarized  in  Table  2.  
The   identification  of   inflammatory  cytokines  has  been  a  great  success  story:   tumor  
necrosis  factor  (TNF)  was  discovered  as  an   inflammatory  mediator   in  1985  (7)  and  
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by  1998  anti-­TNF  antibodies  were  approved  for  use  in  inflammatory  disease.  Other  
cytokines  inhibitors  followed  to  block  interleukins  (IL-­)  IL-­6,  IL-­1  and  IL-­17.    
It  may  be  worth  noting  that  most  known  cytokines  have  been  discovered  either  by  in-­
silico  mining  or  by  biochemical  purification  of  proteins  with  a  biological  activity.  So  
far,  we  think  that  the  only  “cytokine”  discovered  by  proteomics  is  HMGB1,  which  was  
observed   as   it   was   identified   in   Coomassie   blue   stained   gels   as   differentially  
expressed   in   the   supernatant   of   macrophages   stimulated   with   LPS   compared   to  
unstimulated   ones   (97).   Thus,   the   study   of   the   redox   secretome  may   lead   to   the  
identification   of   previously   unrecognized   mediators   and   potential   pharmacological  
targets.  
As  mentioned   above,   PRDX1,   PRDX2   and   FGF1   are   secreted   via   disulfide-­linked  
homodimerization.   It   will   be   interesting   to   investigate   whether   other   proteins   are  
secreted  via  formation  of  a  disulfide-­linked  dimer  as  this  may  eventually  describe  a  
family  of  proteins  whose  secretion  is  dependent  on  the  redox  state  of  the  cell  and/or  
the  extracellular  environment.  
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LIST  OF  ABBREVIATIONS  
  
2-­DE=two-­dimensional  electrophoresis  
AQA=  absolute  quantification  
BioGEE=  biotinoylated  GSH  ethyl  ester  
CE=  Capillary  electrophoresis  
Cys=cysteine  
DIGE=difference  gel  electrophoresis  
DTT=  dithiothreitol  
ECL=  enhanced  chemiluminescence  
ELISA,  enzyme-­linked  immunosorbent  assay  
ESI=  electrospray  ionization  interface  
FASP=  Filter  Aided  Sample  Preparation  
FGF1=  fibroblast  growth  factor  1  
GSH=glutathione  (reduced)  
GSSG=glutathione  disulphide  
HMGB1=  High-­mobility  group  protein  box  1  
HPLC=high-­pressure  liquid  chromatography  
ICAT=  isotope-­coded  affinity  tags  
IEF=  isoelectric  focusing  
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IL=interleukin  
IL-­1sRII=soluble  IL-­1  receptor  type  II  
ITRAQ=  isobaric  tags  for  absolute  and  relative  quantification  
LC-­MS/MS=liquid  chromatography  tandem-­mass  spectrometry  
LPS=lipopolysaccharide  
MALDI=  matrix-­assisted  laser  desorption/ionization  







RPLC=  reverse  phase  liquid  chromatography  
SCX=  strong  cation  exchange  
SDS-­PAGE=  sodium  dodecyl  sulfate-­polyacrylamide  gel  electrophoresis  
SILAC=  stable  isotope  labeling  by  amino  acids  in  cell  culture  
SRM=  selected  reaction  monitoring  
TMT=  tandem  mass  tags  
TNF=tumor  necrosis  factor  
TOF=time  of  flight  
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TXN=thioredoxin     
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Table  1.  Glutathionylated  proteins  in  the  inflammatory  secretome  
Protein   No  of  cysteines   Notes  
Thioredoxin-­1   5     
Peroxiredoxin-­1   4   Dimer  
Peroxiredoxin-­2   3   Dimer  
Profilin-­1   3     
Vimentin   1     
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Table  2.  Cytokine-­like  activities  of  redox  enzymes  
Enzyme   Secretion   Circulating   Extracellular  Activity  
Thioredoxin  






Several  diseases   T  cell  proliferation  and  
activation  (1,96)  







Glutaredoxin   Monocytes   Plasma   (64);;  
diabetes  
Cytoprotection  
NF-­kB   activation   (in  
neurons)  (31)  
Peroxiredoxin  1/2   Monocytes   Various  diseases   Proinflammatory  
(81,86)  
NK   cell   enhancing  
factors  (85)  
Protein   disulfide  
isomerase  
   Various  cells  (48)   Integrin   regulation,  




Muscle   cells  
(26)   (leader  
peptide)  
   H2O2  detoxification  (8)  
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FIGURE  LEGENDS  
  
FIG.  1.  Different  redox  states  of  protein  cysteines.  
  
FIG.   2.  Glycolitic   enzymes   targeted  by  glutathionylation.   The   figure   shows   the  
enzymes   undergoing   glutathionylation   and   those   whose   enzymatic   activity,  
according  to  previous  literature,  is  affected  by  thiol  oxidation.  Based  on  ref.  (44).  
  
FIG.  3.  Concentration  of  different  thiols  in  cells  and  plasma.    
cysteine   free   cysteine;;   GSH,   glutathione   (reduced);;   PSSC,   cysteinylated   proteins;;  
PSSG,  glutathionylated  proteins.  
  
FIG.  4.  Affinity-­enrichment  of  glutathionylated  proteins  for  proteomics  studies.  
Elution   of   proteins   with   DTT   reduces   the   disulfide   bond   thus   eluting   only   those  
proteins  attached  though  glutathionylation.  
  
FIG.5.   Workflow   of   MS-­based   proteomic   provided   tools   for   targeted   or   non  
targeted  protein  identification  and  quantification  approach.  Different  techniques  
used:   e.g.   samples   preparation,   proteins/peptides   pre-­fractionation   methods,   MS-­
based  proteomic  approaches  and  data  analysis  tools  are  presented.    
  
FIG.6.  Workflow  for  redox  arrays  that  identify  glutathionylated  proteins.    
  
FIG.   7.   Different   recovery   of   low-­abundance   glutathionylated   proteins   with  
different  techniques.    Panel  A  shows  the  expected  frequency  distribution;;  panels  B-­
E  show   the  observed   frequency  distribution   from   the  studies   referred   to   in   the   text  
compared   to   the   expected   one.   References   are:   expected   frequency   distribution,  
Beck   et   al   2011   (4);;   2D-­gel   approach,   Fratelli   et   al.,   2002   (38);;   BioGEE/MS  
approach,   Checconi   et   al.   2015   (23);;   dbGSH,  
(http://csb.cse.yzu.edu.tw/dbGSH/)(24);;  redox  arrays,  Mullen  et  al.  2015  (70).  
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